antagonists (MRAs) on cardiac remodeling so far is lacking. We aimed to evaluate the impact of MRAs on changes in cardiac structure and function of left ventricular dysfunction.
It is universally accepted that cardiac remodeling is a core pathogenetic feature of left ventricular dysfunction. Several clinical trials have been undertaken to explore the potential impact of MRAs on cardiac remodeling in patients with heart failure or myocardial infarction; however, a comprehensive evaluation of this impact so far is lacking. Given the accumulating data, there is a need to synthesize available randomized controlled trials (RCTs) regarding the changes of cardiac structure and function impacted by MRAs in patients with left ventricular dysfunction.
Methods
We carried out this meta-analysis of RCTs in accordance with standards set forth by the eplerenone. The following subject terms were used in the search: "aldosterone receptor antagonist", "aldosterone antagonist", "mineralocorticoid receptor", "aldosterone blockade", "spironolactone or Aldactone", "canrenoate or potassium canrenoate or canrenone or canrenoic acid", "eplerenone or Inspra", combined with "heart failure", "myocardial infarction", "cardiac dysfunction", "cardiac insufficiency", "cardiac inadequacy", or "ventricular dysfunction". The search was supplemented by reviews of reference lists, hand-searching of relevant journals, and correspondence with the authors.
Search results were limited to "clinical trials" and "English language".
Trial Selection
Two investigators (X.L. and W.N.) independently obtained the full texts of articles identified as potentially eligible based on the titles and abstracts. If necessary, we emailed the contributing authors to avoid double counting of participants recruited in more than one trial by the same group. Where more than one publication of a trial existed, we abstracted data from the most recent or most complete publication.
Inclusion/Exclusion Criteria
Because relative to heart failure with reduced ejection fraction (HFREF) there are relatively few MRA-therapy trials on heart failure with preserved ejection fraction (HFPEF), and on the premise that HFREF and HFPEF have a different pathophysiology, 5 we, in this meta-analysis, focused only on HFREF in trials involving patients with heart failure. For inclusion, trials had to be conducted in a randomized manner, involve patients with HFREF or myocardial infarction, and examine the usage of MRAs versus placebo or active controls.
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Data Extraction
Two investigators (X.L. and W.N.) independently extracted data using a standardized Excel template. Disagreements were resolved by consensus or by a third investigator (N.J.).
Quality assessment was evaluated by a modified Jadad score, 6 with total scores ranging from 0 (worst) to 5 (best). Hyperkalemia is defined as a potassium level greater than 5.0 mmol/L.
Statistical Analysis
For a certain outcome, where data from three or more unduplicated trials were available, a meta-analysis was performed. Quantitative outcomes changing from baseline to follow-up were summarized and compared by weighted mean difference (WMD) with 95% confidence interval (95% CI) between treatment group and control group. Pearson correlation analyses were employed to test relationships between outcomes. The random-effects model using the DerSimonian & Laird method 7 was employed irrespective of heterogeneity. Heterogeneity was assessed by 2 test and quantified using the inconsistency index (I 2 ) statistic, which ranges from 0% to 100% and is defined as the percentage of the observed between-trial variability that is due to heterogeneity rather than chance.
Predefined subgroup analyses were conducted a priori according to subtypes of left ventricular dysfunction (HFREF and myocardial infarction), treatment durations ( 3 months, (3, 6] months and >6 months), and MRAs (spironolactone, canrenoate and eplerenone). If a given trial can be split into two or more separate studies due to different 
Results

Eligible Trials
Characteristics of the trials included in this meta-analysis are presented in Tables 1 and 2 
Quality Assessment
Various tools have been designed to perform study quality assessment, and the Jadad score is frequently used to assess the quality of RCTs. 28 In this meta-analysis, we employed a modified Jadad scoring system developed by Crowther et al. 6 Quality assessment was performed in duplicate with agreement rate of 0.96, and its details are described in Supplementary Table S1 . The scores of individual trials ranged from 2 to 5 (mean: 3.84; SD:
1.26) out of a maximal score of 5.
Indexes of Cardiac Structure and Function
Overall effect estimates and subgroup analyses by subtypes of left ventricular dysfunction were presented in Figure 2 , and subgroup analyses by treatment durations and MRAs were presented in Table 3 . When all trials were brought into the meta-analysis, improvement was obtained for LVEF (WMD; 95% CI; P: 2.97; 2.26 to 3.67; <0.0005), LVESVI (-5.64; -7.94 to -3.34; <0.0005), and LVEDVI (-7.46; -11.63 to -3.3; <0.0005) ( Figure 2 ). There was no evidence of heterogeneity except for LVEDVI (I 2 =53.9%), and low probability of publication bias as reflected by the Begg's (Supplementary Figure S1 ), Egger's (Supplementary Figure S2 ) and Filled (Supplementary Figure S3 ) funnel plots. n l l al l l l lys ys ys ys ys ys ysis is is is is is is, , , , , , , we we we we we we we e e e e e e emp mp mp mp mp mp mpl l l l l l l s t p d Table S1 . (Table 3) . As for LVESVI and LVEDVI, significance was attained in patients with myocardial infarction, treated 6 months and with spironolactone or canrenoate. Considering the possibility that the more sustained effect of MRAs on chronic heart failure might dilute its robust early effect on post myocardial infarction, further subgroup analyses were undertaken for LVESVI and LVEDVI by treatment durations in patients with HFREF and myocardial infarction, respectively (Supplementary Figure S4 ). As expected in myocardial infarction patients, significance was found in trials with treatment 3 and (3, 6] months; as the durations increased, the extent of reduction in LVESVI and LVEDVI was weakened or became non-significant. In contrast, there was no clear tendency and statistical significance in trials involving HFREF patients.
Serum Indicators
Overall effect estimates and subgroup analyses by subtypes of left ventricular dysfunction were presented in Figure 3 , and subgroup analyses by treatment durations and MRAs were presented in Table 4 . Pooling the results of all qualified trials found a significant reduction in serum PIIINP (WMD; 95% CI; P: -1.12; -1.49 to -0.74; <0.0005) and BNP (-67.06; -91.24 to -42.88; <0.0005), with no evidence of heterogeneity or publication bias There was no significant correlation between BNP and LVEF (data not shown). As expected, serum creatinine (0.05; 0.04 to 0.07; <0.0005) and potassium (0.22; 0.02 to 0.42; 0.034) were higher in MRA treatment group than in placebo or active control group (data not shown).
In subgroup analyses, MRA treatment was observed to reduce serum PIIINP across subgroups by subtypes of left ventricular dysfunction ( Figure 3 ) and by treatment durations, as well as in subgroups limited to spironolactone or canrenoate ( Table 4 ). The longer the duration in treatment, the greater the reduction in PIIINP. Moreover, serum BNP in patients treated (3, 6] and >6 months or with spironolactone or with HFREF was remarkably lower than that of patients receiving placebo or active treatment.
Echo Indexes of Diastolic Function
Overall effect estimates and subgroup analyses by subtypes of left ventricular dysfunction were presented in Figure 4 , and subgroup analyses by treatment durations and MRAs were presented in Table 5 . Among all independent trials, overall estimates reached significance for E (WMD; 95% CI; P: -9.57; -12.98 to -6.17; <0.0005) and DT (7.08; 4.07 to 10.09;
<0.0005), without heterogeneity or publication bias. Further subgroup analyses revealed improvement on E and DT in trials with treatment 6 months, and effects of spironolactone and canrenoate were more prominent on E and DT, respectively. Significant reduction was also identified for IVRT in trials with treatment 3 months or with canrenoate. There was no detectable heterogeneity across aforementioned subgroups. 
Sensitivity and Meta-regression Analyses
Safety and Adverse Events
The frequency of hyperkalemia was higher in MRA treatment group (mean: 6.16%; SD:
1.62%) than in placebo or active control group (mean: 1.68% and SD: 0.94%) (P=0.0018).
There was no difference in frequencies for gynecomastia between the two groups.
Discussion
The It is also of interest to note that as the treatment duration increased, the extent of onin in in in in in inva va va va va va vasi si si si si si sive ve ve ve ve ve ve i i i i i i ind nd nd nd nd nd ndic ic ic ic ic ic ica a a a a a a a e p s m w age e ge ge gen n n n n cont nt nt nt nten en en n nt t t, t t and they are correlat at at at ate ed well. 32, 33 T T T T Th h he h h re is indirect e per er er er erim im im im iment t t t th t t t t at a at ald ld ldoste te te te tero ro ro ro rone ne ne ne ne c c can an an an an st ti t mu m mula a a a ate e te te te c c c c col ol ol olla la la la age ge ge ge g n n n pr pr pr pr prod od od od oduc c c c cti ti ti ti tion o on. 34 MRAs to prove its predictive value in cardiovascular events. Nevertheless, for practical reasons, we hope that this study will not remain just another endpoint of research instead of a beginning to establish the background data to understand the roles of MRAs in cardiac structure and function.
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Question 7.
Were the withdrawals and dropouts described? If yes, score 1 point. 
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